Oxygen concentrator maker Inogen's prelim Q4 revenue grows 2% on strong B2B performance

Inogen

12/01/2026 13:41

Overview

Medical technology firm's preliminary Q4 revenue grew 2%

Company expects positive Adjusted EBITDA for full yr 2025

Outlook

Company to provide 2026 financial guidance during February earnings call

Result Drivers

ORDER TIMING SHIFT - Q4 revenue impacted by delay in large customer orders to 2026, per CEO Kevin Smith

B2B CHANNELS - Strong performance in business-to-business channels contributed to Q4 results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$82 mln
$88.60 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inogen Inc is $13.00, about 84.9% above its January 9 closing price of $7.03

Press Release: ID:nBw4jRZVda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)